This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Effirma

Mylan Inc.

Drug Names(s): Oral flupirtine

Description: Flupirtine is a nonopiate analgesic. Flupirtine acts in the central nervous system through nonopiate pain pathways, possibly involving the thalamus or spinal pain pathways. Flupirtine has strong inhibitory actions on NMDA-mediated neurotransmission.

Deal Structure: Adeona and Meda
In May 2010, Adeona Pharmaceuticals announced that it entered into a corporate partnership with Meda AB, to develop flupirtine for the treatment of fibromyalgia syndrome which contemplates the payment to Adeona of up to $17.5 million in upfront and milestone payments, plus royalties.

Under the terms of the agreement, Adeona has granted Meda an exclusive sublicense to all of Adeona's patents covering the use of flupirtine for fibromyalgia. These patents have been issued in the US and are pending in Canada and Japan (the Territory), i.e., Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia. Meda will assume all future development costs for the commercialization of flupirtine for fibromyalgia. Adeona received an up-front payment of $2.5 million and is entitled to milestone payments of $5 million upon filing of a New Drug Application with the Food and Drug Administration for flupirtine for...See full deal structure in Biomedtracker

Partners: Synthetic Biologics, Inc.


Effirma News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug